Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with…
AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated baseline serum LIGHT levels AVTX-002…